Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LIXT Lixte Biotechnology Holdings Inc.

Trading 03-16 13:31:21 EDT

3.15

+0.04

+1.44%

High3.15	Low3.10	Vol3.30K
Open3.10	D1 Closing3.11	Amplitude1.85%
Mkt Cap27.46M	Tradable Cap25.21M	Total Shares8.70M
T/O10.25K	T/O Rate0.04%	Tradable Shares7.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LIXT","market":"US","secType":"STK","nameCN":"Lixte Biotechnology Holdings Inc.","latestPrice":3.1549,"timestamp":1773681331582,"preClose":3.11,"halted":0,"volume":3299,"delay":0,"changeRate":0.014437299035369828,"floatShares":7992100,"shares":8703100,"eps":-1.211027,"marketStatus":"Trading","change":0.0449,"latestTime":"03-16 13:31:21 EDT","open":3.1,"high":3.1549,"low":3.0975,"amount":10250.8563483,"amplitude":0.018457,"askPrice":3.27,"askSize":400,"bidPrice":2.98,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.211027,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773691200000},"marketStatusCode":2,"adr":0,"listingDate":1606280400000,"exchange":"NASDAQ","adjPreClose":3.11,"postHourTrading":{"tag":"盘后","latestPrice":3.11,"preClose":3.11,"latestTime":"18:14 EDT","volume":4,"amount":12,"timestamp":1773440064634,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.148516},"requestUrl":"/m/hq/s/LIXT/tweets","defaultTab":"tweets","newsList":[{"id":"2618130848","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130848","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130848?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:42","pubTimestamp":1773322938,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nAQN2LPUEK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2618296117","title":"Lixte Amends Share Exchange, Clarifies Liora Ownership Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2618296117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618296117?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:43","pubTimestamp":1773175399,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings ( ($LIXT) ) just unveiled an update. On March 6, 2026, Lixte Biotechnology Holdings, Liora Technologies Europe and Orb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lixte-amends-share-exchange-clarifies-liora-ownership-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lixte-amends-share-exchange-clarifies-liora-ownership-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2618646952","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618646952?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:00","pubTimestamp":1773158410,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 10th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ:LIXT), a clinical-stage pharmaceutical company, re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-adds-innovative-light-therapy-to-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-adds-innovative-light-therapy-to-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNQmain","QYLG","QLD","QID","USJW.SI","LIXT","PSQ","GPIQ","QQQY","NVIW.SI",".IXIC","SQQQ","NQmain","USAW.SI","QQQJ","TSYW.SI","BK4139","TQQQ","JEPQ","QQQE"],"gpt_icon":0},{"id":"2618317678","title":"LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2618317678","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618317678?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:00","pubTimestamp":1773072015,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, March 9th, 2026, FinanceWire The promise of immunotherapy lies in its ability to harness the body’s own immune ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-advances-lead-compound-in-tumor-immunogenicity-research?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-advances-lead-compound-in-tumor-immunogenicity-research?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","QQQE","QQQJ","SQQQ","QQQY","JEPQ","GPIQ","LIXT","BK4139","USAW.SI","TQQQ","NVIW.SI","USJW.SI","QYLG","NQmain","QYLD","PSQ","QID","MNQmain","TSYW.SI","QLD"],"gpt_icon":0},{"id":"2618626333","title":"Powell Max names Geordan Pursglove chairman and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2618626333","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618626333?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059456,"startTime":"0","endTime":"0","summary":"Powell Max appointed Geordan Pursglove as chairman and CEO. Pursglove is chairman and CEO of Lixte Biotechnology and managing director of 2GP Group. The company also added Andrew Hancox, Phillip Balatsos, Caroline Castleforte, and Lourdes Felix to its board. Hancox is founder and managing member of Block 8 Ventures, while Felix is CEO and CFO of BioCorRx.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLbpJfm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4185","BK4585","NDAQ","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4139","PMAX","IE00B64PRP62.GBP","BK4588","SG9999014005.SGD","LIXT","IE00BKPKM429.USD","SG9999014021.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","BICX"],"gpt_icon":0},{"id":"2618362660","title":"Powell Max Limited Successfully Repositions for Its Next Phase of Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2618362660","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618362660?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059400,"startTime":"0","endTime":"0","summary":"Hong Kong, TX, March  09, 2026  (GLOBE NEWSWIRE) --  Powell Max Limited (Nasdaq: PMAX)(“Powell Max” or the “Company”), a financial communications services provider, is pleased to provide the following","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251816/0/en/Powell-Max-Limited-Successfully-Repositions-for-Its-Next-Phase-of-Growth.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRHC","LU2229751404.USD","BK4567","IE00BN0W2T93.GBP","LIXT","GRDX","BK4233","IE00BN0W2W23.USD","BK4096","LU2089279066.USD","CISO","PMAX","BK4079","LU2092937221.SGD","LU2413666426.HKD","LU2413666699.HKD","LU0347712357.USD","LU1543694498.USD","A","BK4585","LU1165135440.EUR","LU2041044095.USD","BK4112","BK4205","LU1721428933.USD","BK4588","BK4121","IE00BN0W2V16.EUR","ALBT","BK4139","BK4134"],"gpt_icon":0},{"id":"2612244011","title":"LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2612244011","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612244011?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:00","pubTimestamp":1771434016,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, February 18th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-appoints-sidney-braun-as-ceo-of-liora-technologies-europe-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-appoints-sidney-braun-as-ceo-of-liora-technologies-europe-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIXT","USAW.SI",".IXIC","BK4139","GPIQ","USJW.SI","QLD","QQQJ","MNQmain","QYLD","QID","QQQY","NVIW.SI","NQmain","JEPQ","QYLG","TSYW.SI","SQQQ","PSQ","QQQE","TQQQ"],"gpt_icon":0},{"id":"2612445104","title":"Lixte Subsidiary Liora Technologies Europe Names Sidney Braun CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445104","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445104?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:04","pubTimestamp":1771419845,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. appointed healthcare industry veteran Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary. Liora is developing electronically controlled proton therapy systems, including its LiGHT System technology for treating tumors with proton therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL5QzQ8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD","LIXT","SG9999014013.SGD","BK4588","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2612610445","title":"Lixte Biotechnology Appoints Sidney Braun as CEO of Its Liora Technologies Europe Ltd. Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2612610445","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612610445?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:00","pubTimestamp":1771419606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nTUA9GR9PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2610668583","title":"LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2610668583","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610668583?lang=en_us&edition=fundamental","pubTime":"2026-02-10 02:30","pubTimestamp":1770661807,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, February 9th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-positions-lb-100-to-expand-effectiveness-of-standard-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-nasdaq-lixt-positions-lb-100-to-expand-effectiveness-of-standard-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","NDX","QID","BK4233","MNQmain","USJW.SI","NVIW.SI","QQQE","PSQ","NQmain","QQQY","GPIQ","TQQQ","LIXT",".IXIC","TSYW.SI","LB","SMP","QQQM","QQQ","QYLG","BK4124","QYLD","SQQQ","QQQJ","QLD","USAW.SI","JEPQ","BK4139"],"gpt_icon":0},{"id":"2609585670","title":"Improving the Odds: How LIXTE Biotechnology (NASDAQ: LIXT) Is Working to Make Cancer Therapies More Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2609585670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609585670?lang=en_us&edition=fundamental","pubTime":"2026-02-06 02:30","pubTimestamp":1770316214,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, February 5th, 2026, FinanceWire LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/improving-the-odds-how-lixte-biotechnology-nasdaq-lixt-is-working-to-make-cancer-therapies-more-effective?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/improving-the-odds-how-lixte-biotechnology-nasdaq-lixt-is-working-to-make-cancer-therapies-more-effective?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QID","QYLD","NQmain","NVIW.SI","QQQE","JEPQ","QQQJ","GPIQ","QQQY","MNQmain","LIXT","USAW.SI","PSQ","USJW.SI","SQQQ","QYLG","BK4139","TSYW.SI","QLD",".IXIC","TQQQ"],"gpt_icon":0},{"id":"2605022134","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2605022134","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605022134?lang=en_us&edition=fundamental","pubTime":"2026-01-24 01:30","pubTimestamp":1769189421,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, January 23rd, 2026, FinanceWire LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-advances-a-novel-approach-to-enhancing-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-advances-a-novel-approach-to-enhancing-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","QLD","MNQmain","QID","TQQQ","QQQE","QYLD","SQQQ","GPIQ","NVIW.SI","BK4139","JEPQ","NQmain","QQQY","PSQ","TSYW.SI","LIXT","QYLG","USJW.SI","QQQJ","USAW.SI"],"gpt_icon":0},{"id":"2605818664","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2605818664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605818664?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:30","pubTimestamp":1769013015,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, January 21st, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-sponsors-good-health-mind-body-and-soul-summit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-sponsors-good-health-mind-body-and-soul-summit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QYLD","QQQE","SMMF","LIXT","GPIQ","QQQM","QID","TSYW.SI","QYLG","QQQY","NQmain","PSQ","TQQQ","BK4139","NVIW.SI","MNQmain","BK4211","QQQJ","USAW.SI","JEPQ",".IXIC","QLD","USJW.SI","SQQQ"],"gpt_icon":0},{"id":"2604113199","title":"Lixte Biotechnology Holdings to Participate in DealFlow Discovery Conference in Atlantic City","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113199","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113199?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914017,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc., a clinical-stage pharmaceutical company, will participate in the DealFlow Discovery Conference in Atlantic City, New Jersey, on January 28-29, 2026. CEO Geordan Pursglove is scheduled to conduct one-on-one meetings with investors during the event, which will be held at The Borgata Hotel, Casino & Spa.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL5glpcq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","NDAQ","LIXT","LU2095319765.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","BK4112","BK4585","LU2210149790.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2602915053","title":"LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2602915053","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602915053?lang=en_us&edition=fundamental","pubTime":"2026-01-09 01:00","pubTimestamp":1767891614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, January 8th, 2026, FinanceWire LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collabo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-expands-ovarian-cancer-trial-with-md-anderson-and-gsk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/lixte-biotechnology-holdings-nasdaq-lixt-expands-ovarian-cancer-trial-with-md-anderson-and-gsk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","TSYW.SI","TQQQ","USAW.SI","PSQ","BK4139","NQmain","GSK","QLD","SQQQ","MNQmain","LIXT","USJW.SI","BK4585","BK4007","MD","GSK.UK",".IXIC","BK4196","QID","BK4532","NVIW.SI","LU1829250122.USD"],"gpt_icon":0},{"id":"2600709771","title":"Lixte Biotechnology Announces Unregistered Share Exchange with Orbit Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2600709771","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600709771?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:01","pubTimestamp":1767214883,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has announced the completion of a share exchange agreement with Orbit Capital Inc. Under the terms of the agreement, Orbit Capital exchanged 2,700 shares of Lixte’s Series C Preferred Stock for 700,000 shares of Lixte’s common stock and 200 ordinary shares, representing 20% of the outstanding securities, of Lixte’s wholly-owned subsidiary, Liora Technologies Europe Ltd. The transaction, which resulted in the cancellation of all Series C Preferred Shares, was conducted as an unregistered sale of equity securities under exemptions provided by Section 4 and/or Rule 506 of Regulation D of the Securities Act of 1933.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL4BF2Yd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"gpt_icon":0},{"id":"2593027490","title":"Lixte Biotechnology Holdings Inc - Expands Collaboration With University of Texas Md Anderson Cancer Center & GSK for Lb-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2593027490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593027490?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:12","pubTimestamp":1766495559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0MB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1481599808.USD","LU1228905037.USD","LU1670756490.USD","LU1645745479.HKD","LU1400636491.USD","LU0306806265.USD","IE00B3T34201.USD","LU1228905540.USD","LU0971552830.HKD","LU0321505868.SGD","LU1302929846.USD","LU0161305163.EUR","LU0225284248.USD","LU0306807586.USD","GSK.UK","LU0058720904.USD","LU0203345920.USD","LU0211331839.USD","LU1309081286.SGD","LU1400636574.HKD","LU1098665638.USD","BK5011","LU1400636657.SGD","LU1035777561.USD","LU0109981661.USD","IE00BQJZX424.USD","LU1046248800.SGD","LU1481600234.SGD","LU0225771236.USD","LU0985481810.HKD","LU0321505439.SGD","LU1064927863.SGD","LU1015430645.USD","LIXT","LU0203347892.USD","LU1202635105.USD","IE00BWDBJ516.SGD","BK4139","IE0034235071.USD","LU0289739699.SGD","LU0971552673.USD","LU1487256676.USD","LU0575583348.USD","LU0545562505.USD"],"gpt_icon":0},{"id":"2593490476","title":"Lixte Biotechnology Expands Ovarian Cancer Trial With MD Anderson and GSK","url":"https://stock-news.laohu8.com/highlight/detail?id=2593490476","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593490476?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:01","pubTimestamp":1766494869,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. has expanded its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on a clinical trial investigating Lixte’s proprietary compound, LB-100, for the treatment of ovarian clear cell cancer. The trial, which combines LB-100 with GSK's immunotherapy drug Dostarlimab, began in January 2024 and has recently added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The expanded partnership will double trial enrollment to 42 patients, with initial findings from the first 21 patients expected to be presented in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. pub","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL4RZhr4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","BK4112","NDAQ","BK4139","LU2210150020.SGD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","LIXT","SG9999014013.SGD"],"gpt_icon":0},{"id":"2592904336","title":"Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2592904336","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592904336?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:00","pubTimestamp":1766066400,"startTime":"0","endTime":"0","summary":"BOCA RATON, FLA, Dec.  18, 2025  (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3207816/0/en/Lixte-Biotechnology-Holdings-Inc-Announces-4-3-Million-Registered-Direct-Offering-Priced-at-the-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0},{"id":"2590546572","title":"Lixte Biotechnology Holdings Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546572","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590546572?lang=en_us&edition=fundamental","pubTime":"2025-12-12 03:52","pubTimestamp":1765482745,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. held its Annual Meeting on December 8, 2025. Shareholders approved the election of Geordan Pursglove, Jason Sawyer, Dr. Michael Holloway, Lourdes Felix, and Guy Primus to the board of directors. The appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. Shareholders also approved an amendment to the 2020 Plan, increasing the number of shares of common stock available for issuance from 2.75 million to 3.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLCR9SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIXT","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lixte.com","stockEarnings":[{"period":"1week","weight":0.2746},{"period":"1month","weight":0.0163},{"period":"3month","weight":-0.2321},{"period":"6month","weight":-0.4821},{"period":"1year","weight":1.5917},{"period":"ytd","weight":-0.2087}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.153774},{"month":2,"riseRate":0.625,"avgChangeRate":0.06495},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03193},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.105051},{"month":5,"riseRate":0.375,"avgChangeRate":-0.005082},{"month":6,"riseRate":0.5,"avgChangeRate":0.031165},{"month":7,"riseRate":0.625,"avgChangeRate":0.400968},{"month":8,"riseRate":0.5,"avgChangeRate":0.097631},{"month":9,"riseRate":0.375,"avgChangeRate":0.00973},{"month":10,"riseRate":0.375,"avgChangeRate":-0.019298},{"month":11,"riseRate":0.375,"avgChangeRate":-0.035386},{"month":12,"riseRate":0.25,"avgChangeRate":-0.145393}],"exchange":"NASDAQ","name":"Lixte Biotechnology Holdings Inc.","nameEN":"Lixte Biotechnology Holdings Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lixte Biotechnology Holdings Inc.,LIXT,Lixte Biotechnology Holdings Inc.股票,Lixte Biotechnology Holdings Inc.股票老虎,Lixte Biotechnology Holdings Inc.股票老虎国际,Lixte Biotechnology Holdings Inc.行情,Lixte Biotechnology Holdings Inc.股票行情,Lixte Biotechnology Holdings Inc.股价,Lixte Biotechnology Holdings Inc.股市,Lixte Biotechnology Holdings Inc.股票价格,Lixte Biotechnology Holdings Inc.股票交易,Lixte Biotechnology Holdings Inc.股票购买,Lixte Biotechnology Holdings Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lixte Biotechnology Holdings Inc.(LIXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lixte Biotechnology Holdings Inc.(LIXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}